申请人:Bayer Aktiengesellschaft
公开号:US05137881A1
公开(公告)日:1992-08-11
Substituted pyrido-oxazines can be prepared by reduction of the corresponding ketones. They are useful active compounds in medicaments, in particular for the treatment of hyperlipoproteinaemia, lipoproteinaemia and arteriosclerosis.
可以通过还原相应的酮来制备取代吡啶噁嗪。它们是药物中有用的活性化合物,特别适用于治疗高脂蛋白血症、脂蛋白血症和动脉硬化。